AOD-9604

AOD-9604 is a modified peptide derived from the C-terminal region of human growth hormone. It has been investigated in metabolic and adipose-tissue research, including earlier clinical development programs.

Designed to study metabolic signaling associated with a fragment of growth hormone without reproducing the full receptor profile of intact growth hormone. Proposed lipolytic pathways remain an area of investigation.

Limited human evidence with substantial uncertainty; additional preclinical literature exists.

Level III, Limited human evidence

Earlier clinical development did not establish an approved therapeutic use. Findings are inconsistent across study types, and many commercial claims exceed the published evidence.

FDA has identified safety-information gaps and potential concerns for compounded use. Comprehensive modern human safety data are limited.

No FDA-approved drug product; identified by FDA among substances requiring additional safety evaluation for compounding.

Supplied strictly for in-vitro and ex-vivo laboratory research. Not for human or veterinary administration, diagnostic, or therapeutic use. Import and regulatory compliance remain the responsibility of the receiving researcher.

• AOD-9604, 5 mgLyophilized
• AOD-9604, 10 mgLyophilized

Every Cendrix lot ships with an HPLC purity chromatogram, mass-spectrometry identity confirmation, appearance and reconstitution observations, and endotoxin testing where applicable. Lot certificates are retrievable from the Quality page using the lot number printed on the vial.

External searches link to PubMed, ClinicalTrials.gov, Google Scholar, and FDA records. Cendrix does not endorse interpretations published in third-party sources.